MTOR and neoplasm: By modulating gut microbiota metabolism to alter the host’s amino acid composition, BJO activates mTOR and exhibits microbiota-dependent inhibition of MDA-MB-231 xenograft tumor growth in mice, with no toxicity observed in non-target organs.